Arrowhead Research Corp. (Nasdaq: ARWR) reported disappointing results from an
ongoing Phase II study of it hepatitis B treatment ARC-520 sending the stock price plummeting $6.00 to $6.51.
Arrowhead Research reports disappointing study results
October 08, 2014 at 14:17 PM EDT
